中华老年心脑血管病杂志

[1] Sarkar S,Raymick J,Imam S. Neuroprotective and therapeutic strategies against Parkinson's disease:recent perspectives[J]. Int J Mol Sci,2016,17(6):E904. DOI:10. 3390/ijms17060904.

[2] Ye ZW,Zhang J,Townsend DM,et al. Oxidative stress,redox regulation and diseases of cellular differentiation[J]. Biochim Biophys Acta,2015,1850(8):1607-1621. DOI:10. 1016/j. bbagen. 2014. 11. 010.

[3] Selivanov VA,Votyakova TV,Pivtoraiko VN,et al. Reactive oxygen species production by forward and reverse electron fluxes in the mitochondrial respiratory chain[J]. PLo S Comput Biol,2011,7(3):e1001115. DOI:10. 1371/journal. pcbi. 1001115.

[4] Brand MD. The sites and topology of mitochondrial superoxide production[J]. Exp Gerontol,2010,45(7-8):466-472. DOI:10. 1016/j. exger. 2010. 01. 003.

[5] Guo C,Sun L,Chen X,et al. Oxidative stress,mitochondrial damage and neurodegenerative diseases[J]. Neural Regen Res,2013,8(21):2003-2014. DOI:10. 3969/j. issn. 1673-5374. 2013.21. 009.

[6] Ren X,Zou L,Zhang X,et al. Redox signaling mediated by thioredoxin and glutathione systems in the central nervous system[J]. Antioxid Redox Signal,2017,27(13):989-1010.DOI:10. 1089/ars. 2016. 6925.

[7] Dias V,Junn E,Mouradian MM. The role of oxidative stress in Parkinson's disease[J]. J Parkinsons Dis,2013,3(4):461-491.DOI:10. 3233/JPD-130230.

[8] Rodriguez M,Rodriguez-Sabate C,Morales I,et al. Parkin-son's disease as a result of aging[J]. Aging Cell,2015,14(3):293-308. DOI:10. 1111/acel. 12312.

[9] Liu Z,Zhou T,Ziegler AC,et al. Oxidative stress in neurodegenerative diseases:from molecular mechanisms to clinical applications[J]. Oxid Med Cell Longev,2017,2017:2525967.DOI:10. 1155/2017/2525967.

[10] Li H,Jiang H,Zhang B,et al. Modeling Parkinson's disease using patient-specific induced pluripotent stem cells[J]. J Parkinsons Dis,2018,8(4):479-493. DOI:10. 3233/JPD-181353.

[11] Nguyen HN,Byers B,Cord B,et al. LRRK2 mutant i PSC-derived DA neurons demonstrate increased susceptibility to oxidative stress[J]. Cell Stem Cell,2011,8(3):267-280. DOI:10.1016/j. stem. 2011. 01. 013.

[12] Puspita L,Chung SY,Shim JW. Oxidative stress and cellular pathologies in Parkinson's disease[J]. Mol Brain,2017,10(1):53.DOI:10. 1186/s13041-017-0340-9.

[13] Bravo R,Parra V,Gatica D,et al. Endoplasmic reticulum and the unfolded protein response:dynamics and metabolic integration[J]. Int Rev Cell Mol Biol,2013,301:215-290. DOI:10.1016/B978-0-12-407704-1. 00005-1.

[14] Ciechanover A,Kwon YT. Protein quality control by molecular chaperones in neurodegeneration[J]. Front Neurosci,2017,11:185. DOI:10. 3389/fnins. 2017. 00185.

[15] Ganguly G,Chakrabarti S,Chatterjee U,et al. Proteinopathy,oxidative stress and mitochondrial dysfunction:cross talk in Alzheimer's disease and Parkinson's disease[J]. Drug Des Devel Ther,2017,11:797-810. DOI:10. 2147/DDDT. S130514.

[16] Sweeney P,Park H,Baumann M,et al. Protein misfolding in neurodegenerative diseases:implications and strategies[J]. Transl Neurodegener,2017,6:6. DOI:10. 1186/s40035-017-0077-5.

[17] Benskey MJ,Perez RG,Manfredsson FP. The contribution of alpha synuclein to neuronal survival and function-implications for Parkinson's disease[J]. J Neurochem,2016,137(3):331-359.DOI:10. 1111/jnc. 13570.

[18] BurréJ,Sharma M,Tsetsenis T,et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro[J]. Science,2010,329(5999):1663-1667. DOI:10. 1126/science.1195227.

[19] Shamoto-Nagai M,Hisaka S,Naoi M,et al. Modification ofα-synuclein by lipid peroxidation products derived from polyunsaturated fatty acids promotes toxic oligomerization:its relevance to Parkinson disease[J]. J Clin Biochem Nutr,2018,62(3):207-212. DOI:10. 3164/jcbn. 18-25.

[20] Oliveras-SalváM,Van der Perren A,Casadei N,et al. r AAV2/7vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration[J]. Mol Neurodegener,2013,8:44.DOI:10. 1186/1750-1326-8-44.

[21] Ingelsson M. Alpha-synuclein oligomers-neurotoxic molecules in Parkinson's disease and other Lewy body disorders[J]. Front Neurosci,2016,10:408. DOI:10. 3389/fnins. 2016. 00408.

[22] Houlden H,Singleton AB. The genetics and neuropathology of Parkinson's disease[J]. Acta Neuropathol,2012,124(3):325-338. DOI:10. 1007/s00401-012-1013-5.

[23] Deas E,Cremades N,Angelova PR,et al. Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease[J]. Antioxid Redox Signal,2016,24(7):376-391. DOI:10. 1089/ars. 2015. 6343.

[24] Chung SY,Kishinevsky S,Mazzulli JR,et al. Parkin and PINK1patient i PSC-derived midbrain dopamine neurons exhibit mitochondrial dysfunction andα-synuclein accumulation[J]. Stem Cell Reports,2016,7(4):664-677. DOI:10. 1016/j. stemcr.2016. 08. 012.

[25] H9hn A,Weber D,Jung T,et al. Happily never after:aging in the context of oxidative stress,proteostasis loss and cellular senescence[J]. Redox Biol,2017,11:482-501. DOI:10. 1016/j.redox. 2016. 12. 001.

[26] Angelova PR,Abramov AY. Alpha-synuclein and beta-amyloiddifferent targets,same players:calcium,free radicals and mitochondria in the mechanism of neurodegeneration[J]. Biochem Biophys Res Commun,2017,483(4):1110-1115. DOI:10.1016/j. bbrc. 2016. 07. 103.

[27] Pisanu A,Lecca D,Mulas G,et al. Dynamic changes in pro-and anti-inflammatory cytokines in microglia after PPAR-γagonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease[J]. Neurobiol Dis,2014,71:280-291.DOI:10. 1016/j. nbd. 2014. 08. 011.

[28] Ha SK,Moon E,Lee P,et al. Acacetin attenuates neuroinflammation via regulation the response to LPS stimuli in vitro and in vivo[J]. Neurochem Res,2012,37(7):1560-1567. DOI:10.1007/s11064-012-0751-z.

[29] Codolo G,Plotegher N,Pozzobon T,et al. Triggering of inflammasome by aggregatedα-synuclein,an inflammatory response in synucleinopathies[J]. PLo S One,2013,8(1):e55375. DOI:10.1371/journal. pone. 0055375.

[30] George J,Goncalves FQ,Cristóv2o G,et al. Different danger signals differently impact on microglial proliferation through alterations of ATP release and extracellular metabolism[J]. Glia,2015,63(9):1636-1645. DOI:10. 1002/glia. 22833.

[31] Qian Y,Yang X,Xu S,et al. Alteration of the fecal microbiota in Chinese patients with Parkinson's disease[J]. Brain Behav Immun,2018,70:194-202. DOI:10. 1016/j. bbi. 2018. 02. 016.

[32] Mulak A. A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease[J]. Mov Disord,2018,33(3):398-401. DOI:10. 1002/mds. 27304.

[33] Sun MF,Shen YQ. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease[J]. Ageing Res Rev,2018,45:53-61. DOI:10. 1016/j. arr. 2018. 04. 004.

[34] Truban D,Hou X,Caulfield TR,et al. PINK1,Parkin,and mitochondrial quality control:what can we learn about Parkinson's disease pathobiology[J]? J Parkinsons Dis,2017,7(1):13-29.DOI:10. 3233/JPD-160989.

[35] Larsen SB,Hanss Z,Krüger R. The genetic architecture of mitochondrial dysfunction in Parkinson's disease[J]. Cell Tissue Res,2018,373(1):21-37. DOI:10. 1007/s00441-017-2768-8.

[36] Chen ML,Wu RM. LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease:a review[J]. J Biomed Sci,2018,25(1):52. DOI:10. 1186/s12929-018-0454-0.